ppms – Scalper1

Roche Drug Scores A Hit Against Stubborn Form Of MS

Swiss pharma giant Roche (RHHBY) was a rare drug stock moving up Monday after its U.S. biotech arm Genentech said its drug candidate succeeded against primary progressive multiple sclerosis (PPMS) in a clinical trial. Roche said its drug ocrelizumab had met the late-stage study’s primary endpoint of showing significantly reduced progression of clinical disability, compared with the placebo group, after 12 weeks of treatment. It will reveal more

Novartis’ Gilenya Fails To Treat Progressive MS

Swiss drug giant Novartis (NVS) said Monday that its oral multiple-sclerosis drug Gilenya failed a late-stage clinical trial for a particularly virulent form of the disease. The company said Gilenya didn’t do better than a placebo in patients with progressive primary multiple sclerosis (PPMS). Unlike the more common relapsing-remitting form of the disease, PPMS brings neurologic decline from the outset but with fewer visible symptoms, often